Skip to content
Subscriber Only

Vaxart’s 2,000% Rally on Vaccine Pill Leaves Bears on Edge

  • Initial data for Vaxart’s Covid-19 vaccine expected in January
  • Future short selling may be stymied by dwindling availability
Pills pour out of a prescription medication bottle
Pills pour out of a prescription medication bottlePhotographer: DNY59/iStockphoto

Vaxart Inc.’s more than 2,000% rally this year on the promise of an oral Covid-19 vaccine has left the bears betting against it in rough waters. And time will tell if short sellers get a reprieve with clinical data due next month on how well Vaxart’s pill works.

“Most of us associate vaccines with needles,” said Andrei Floroiu, the biotech company’s chief executive officer. “An oral vaccine would be the holy grail.”